Targeted Oncology interviews feature the world's leading oncologists sharing their insights on the latest news and advances in diagnostic testing, biomarkers, pathways, immunotherapy, and targeted therapeutics for better application into clinical practice.
Progression on Ibrutinib With the Acquisition of Resistance Mutations
July 26th 2014Jennifer Woyach, MD, assistant professor of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the association of disease progression on ibrutinib therapy with the acquisition of resistance mutations as seen at The Ohio State University Comprehensive Cancer Center.
Watch
Discontinuing Statins in Patients with Life-Limiting Illnesses
July 21st 2014Amy P. Abernethy, MD, PhD, associate professor, School of Nursing, director, Duke Center for Learning Health Care, Duke University School of Medicine, discusses the results of a multisite randomized trial that examined continuing versus discontinuing statins in the setting of life-limiting illness.
Watch
Are Adjuvant Bisphosphonates a New Standard of Care?
July 19th 2014Adam M. Brufsky, MD, PhD, gives a summary of his talk at the 13th Annual International Congress on the Future of Breast Cancer®. Brufsky discusses whether or not adjuvant bisphosphonates are ready to be a new standard of care in breast cancer.
Watch
The Challenges of Identifying Biomarkers in Lung Cancer
July 18th 2014Edward S. Kim, MD, chairman, Solid Tumor Oncology and Investigational Therapeutics, Levine Cancer Institute, Carolinas HealthCare System, discusses some of the challenges researchers face when it comes to biomarkers in lung cancer.
Watch
Memory T Cell Responses Following Anti-CTLA-4 Antibody Treatment
July 17th 2014Lawrence Fong, MD, associate professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco, discusses research to examine the immunobiology and biomarkers associated with improved clinical outcomes seen during treatment with an anti-CTLA-4 antibody.
Watch
Analysis of a Phase II Study of Cabozantinib in mCRPC
July 15th 2014Edwin M. Posadas, MD, FACP, medical director, Urologic Oncology Program, Cedars-Sinai’s Samuel Oschin Comprehensive Cancer Institute, discusses a translational phase II study of cabozantinib in men with metastatic castration-resistant prostate cancer (mCRPC) with visceral metastases with characterization of circulating tumor cells and large oncosomes.
Watch
The Toxicity of T-DM1 in Breast Cancer Patients with Liver Metastases
July 14th 2014Mark D. Pegram, MD, a professor of medicine at Stanford University Medical Center and the director of the Breast Cancer Program at the Stanford Cancer Institute, discusses the results of a retrospective analysis that examined the toxicity of patients with liver metastases that were enrolled in phase III studies of T-DM1 for metastatic breast cancer.
Watch
An Analysis of the PANORAMA 1 Trial
July 11th 2014Angela Dispenzieri, MD, a professor of medicine in the division of hematology at the Mayo Clinic, discusses the results of the PANORAMA 1 trial: a randomized, double-blind, phase III study of panobinostat or placebo plus bortezomib and dexamethasone in relapsed or relapsed and refractory multiple myeloma.
Watch
MPDL3280A in Patients with Metastatic Bladder Cancer
July 10th 2014Nicholas J. Vogelzang, MD, member of the US Oncology Network, site research leader for Comprehensive Cancer Centers of Nevada, discusses the results of a phase I study that examined the utilization of the anti-PD-L1 antibody MPDL3280A as treatment for patients with metastatic bladder cancer.
Watch
The Tolerability of Sorafenib in Thyroid Cancer
July 9th 2014Marcia S. Brose, MD, PhD, assistant professor, Abramson Cancer Center, Department of Otolaryngology, Head & Neck Surgery, Department of Medicine, Division of Hematology/Oncology, Department of Dermatology, University of Pennsylvania, discusses the tolerability and safety of sorafenib as seen in patients with thyroid cancer.
Watch
Ramucirumab Plus FOLFOX as Front-Line Treatment in Advanced Gastric or Esophageal Cancer
July 8th 2014Johanna Bendell, MD, Director of GI Cancer Research Program, associate director, Drug Development Program, Sarah Cannon Research Institute, discusses the results of a randomized, double-blind, multicenter phase II trial that examined FOLFOX with or without ramucirumab as front-line therapy for advanced gastric or esophageal adenocarcinoma.
Watch
Cell Cycle Progression Score as a Predictor of Progression of ccRCC
July 7th 2014James A. Brown, MD, Professor of Urology, Professor of Biomedical Engineering, University of Iowa Carver College of Medicine, discusses an analysis of cell cycle progression scores in patients with clear cell renal cell carcinoma (ccRCC) to evaluate its prognostic value.
Watch
The DYNAMO Trial: IPI-145 for Refractory Indolent Non-Hodgkin Lymphoma
July 3rd 2014Julian Adams, PhD, president, Research and Development, Infinity Pharmaceuticals, discusses the rationale for a phase II trial looking at IPI-145 for the treatment of patients with refractory indolent non-Hodgkin lymphoma.
Watch